The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended marketing authorization approval for Rhokiinsa for the reduction of IOP in primary open-angle glaucoma or ocular hypertension, Aerie Pharmaceuticals announced in a press release.
Rhokiinsa (netarsudil ophthalmic solution 0.02%) is marketed as Rhopressa in the United States.
“We are delighted that the CHMP has adopted a positive opinion for Rhokiinsa,” Vicente Anido Jr., PhD, chairman and CEO at Aerie, said in the release. “We look forward to the European Commission’s
Uncategorized